An eye on the future of inflammasomes and drug development in AMD

Journal of Molecular Medicine

Volumn 91, Issue 9, 2013, Pages 1059-1070

  Campbell, Matthew ^a   Doyle, Sarah L ^b,c  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c OUR LADY S CHILDREN S HOSPITAL   (Ireland)

Author keywords

Age related macular degeneration (AMD); IL 18; IL 1beta; Inflammasome; NLRP3

Indexed keywords

CRYOPYRIN; CYTOKINE; GAMMA INTERFERON; GSK A 18110040; GSK A18110040; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; MITOCHONDRIAL DNA; MYELOID DIFFERENTIATION FACTOR 88; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 18; RNA; TOLL LIKE RECEPTOR 2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

AGING; ANTIOXIDANT ACTIVITY; BONE MARROW CELL; CARCINOMA; CELL MEMBRANE; CYTOKINE RELEASE; DISEASE COURSE; DONOR; DRUSEN; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; INFLAMMATION; INNATE IMMUNITY; LIFESTYLE MODIFICATION; LYMPHOMA; MACROPHAGE; MELANOMA; MONOCYTE; MUELLER CELL; NERVE CELL MEMBRANE STEADY POTENTIAL; NONHUMAN; ORGAN DONOR; OXIDATIVE STRESS; PARTICULATE MATTER; PATHOGENESIS; PHAGOCYTOSIS; PHAGOLYSOSOME; PHOTORECEPTOR CELL; PIGMENT EPITHELIUM; PNEUMOCOCCAL INFECTION; PROTEIN CLEAVAGE; PROTEIN MODIFICATION; RETINA; RETINA AMACRINE CELL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

ANIMALS; CARRIER PROTEINS; DRUG DISCOVERY; HUMANS; INFLAMMASOMES; INFLAMMATION; MACULAR DEGENERATION;

EID: 84884290172     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-013-1050-0     Document Type: Review

References (75)

1. AC C (1478) De Medicina. Nicolaus Laurentii, Florence
2. Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454:428-435
3. Nathan C (2002) Points of control in inflammation. Nature 420:846-852
4. White ES, Mantovani AR (2013) Inflammation, wound repair, and fibrosis: reassessing the spectrum of tissue injury and resolution. J Pathol 229:141-144
5. Janeway CA, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197-216
6. Kumar H, Kawai T, Akira S (2011) Pathogen recognition by the innate immune system. Int Rev Immunol 30:16-34
7. O'Neill LA, Bowie AG (2007) The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7:353-364
8. Schroder K, Tschopp J (2010) The inflammasomes. Cell 140:821-832
9. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD (2011) The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 17:179-188
10. Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, Brickey WJ, Ting JP (2011) Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 12:408-415
11. Stienstra R, van Diepen JA, Tack CJ, Zaki MH, van de Veerdonk FL, Perera D, Neale GA, Hooiveld GJ, Hijmans A, Vroegrijk I et al (2011) Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci U S A 108:15324-15329
12. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, Becker C, Franchi L, Yoshihara E, Chen Z et al (2010) Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol 11:897-904
13. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685-1695
14. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237-241
15. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9:857-865
16. Drouin-Ouellet J, Cicchetti F (2012) Inflammation and neurodegeneration: the story 'retolled'. Trends Pharmacol Sci 33:542-551
17. Rock KL, Latz E, Ontiveros F, Kono H (2010) The sterile inflammatory response. Annu Rev Immunol 28:321-342
18. Rein DB, Wittenborn JS, Zhang X, Honeycutt AA, Lesesne SB, Saaddine J (2009) Group VHC-ES: forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol 127:533-540
19. Swaroop A, Chew EY, Rickman CB, Abecasis GR (2009) Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. Annu Rev Genomics Hum Genet 10:19-43
20. Gu X, Meer SG, Miyagi M, Rayborn ME, Hollyfield JG, Crabb JW, Salomon RG (2003) Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem 278:42027-42035
21. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST et al (2005) Complement factor H polymorphism in age-related macular degeneration. Science 308:385-389
22. Kinnunen K, Petrovski G, Moe MC, Berta A, Kaarniranta K (2012) Molecular mechanisms of retinal pigment epithelium damage and development of age-related macular degeneration. Acta Ophthalmol 90:299-309
23. Eldred GE (1995) Lipofuscin fluorophore inhibits lysosomal protein degradation and may cause early stages of macular degeneration. Gerontology 41(Suppl 2):15-28
24. Bressler SB, Maguire MG, Bressler NM, Fine SL (1990) Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. The Macular Photocoagulation Study Group. Arch Ophthalmol 108:1442-1447
25. Benhar I, London A, Schwartz M (2012) The privileged immunity of immune privileged organs: the case of the eye. Front Immunol 3:296
26. Krohne TU, Stratmann NK, Kopitz J, Holz FG (2010) Effects of lipid peroxidation products on lipofuscinogenesis and autophagy in human retinal pigment epithelial cells. Exp Eye Res 90:465-471
27. Doyle SL, Campbell M, Ozaki E, Salomon RG, Mori A, Kenna PF, Farrar GJ, Kiang AS, Humphries MM, Lavelle EC et al (2012) NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat Med 18:791-798
28. Tarallo V, Hirano Y, Gelfand BD, Dridi S, Kerur N, Kim Y, Cho WG, Kaneko H, Fowler BJ, Bogdanovich S et al (2012) DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell 149:847-859
29. Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11:373-384
30. Wagner H (2006) Endogenous TLR ligands and autoimmunity. Adv Immunol 91:159-173
31. Yang Z, Stratton C, Francis PJ, Kleinman ME, Tan PL, Gibbs D, Tong Z, Chen H, Constantine R, Yang X et al (2008) Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N Engl J Med 359:1456-1463
32. Zareparsi S, Buraczynska M, Branham KE, Shah S, Eng D, Li M, Pawar H, Yashar BM, Moroi SE, Lichter PR et al (2005) Toll-like receptor 4 variant D299G is associated with susceptibility to age-related macular degeneration. Hum Mol Genet 14:1449-1455
33. Allikmets R, Bergen AA, Dean M, Guymer RH, Hageman GS, Klaver CC, Stefansson K, Weber BH (2009) Consortium IA-rMDG: Geographic atrophy in age-related macular degeneration and TLR3. N Engl J Med 360:2252-2254, author reply 2255-2256
34. Edwards AO, Chen D, Fridley BL, James KM, Wu Y, Abecasis G, Swaroop A, Othman M, Branham K, Iyengar SK et al (2008) Toll-like receptor polymorphisms and age-related macular degeneration. Invest Ophthalmol Vis Sci 49:1652-1659
35. Cho Y, Wang JJ, Chew EY, Ferris FL, Mitchell P, Chan CC, Tuo J (2009) Toll-like receptor polymorphisms and age-related macular degeneration: replication in three case-control samples. Invest Ophthalmol Vis Sci 50:5614-5618
36. Netea MG, Wijmenga C, O'Neill LA (2012) Genetic variation in Toll-like receptors and disease susceptibility. Nat Immunol 13:535-542
37. Dowling JK, O'Neill LA (2012) Biochemical regulation of the inflammasome. Crit Rev Biochem Mol Biol 47:424-443
38. Kauppinen A, Niskanen H, Suuronen T, Kinnunen K, Salminen A, Kaarniranta K (2012) Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells-implications for age-related macular degeneration (AMD). Immunol Lett 147:29-33
39. Tseng WA, Thein T, Kinnunen K, Lashkari K, Gregory MS, D'Amore PA, Ksander BR (2013) NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration. Invest Ophthalmol Vis Sci 54:110-120
40. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M et al (2010) NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464:1357-1361
41. Masters SL, O'Neill LA (2011) Disease-associated amyloid and misfolded protein aggregates activate the inflammasome. Trends Mol Med 17:276-282
42. Schroder K, Zhou R, Tschopp J (2010) The NLRP3 inflammasome: a sensor for metabolic danger? Science 327:296-300
43. Crabb JW, Miyagi M, Gu X, Shadrach K, West KA, Sakaguchi H, Kamei M, Hasan A, Yan L, Rayborn ME et al (2002) Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A 99:14682-14687
44. Dastgheib K, Green WR (1994) Granulomatous reaction to Bruch's membrane in age-related macular degeneration. Arch Ophthalmol 112:813-818
45. West XZ, Malinin NL, Merkulova AA, Tischenko M, Kerr BA, Borden EC, Podrez EA, Salomon RG, Byzova TV (2010) Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 467:972-976
46. Hyttinen JM, Petrovski G, Salminen A, Kaarniranta K (2011) 5'-Adenosine monophosphate-activated protein kinase - mammalian target of rapamycin axis as therapeutic target for age-related macular degeneration. Rejuvenation Res 14:651-660
47. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, Dixit VM (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440:228-232
48. Ichinohe T, Pang IK, Iwasaki A (2010) Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat Immunol 11:404-410
49. Lee GS, Subramanian N, Kim AI, Aksentijevich I, Goldbach-Mansky R, Sacks DB, Germain RN, Kastner DL, Chae JJ (2012) The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature 492:123-127
50. Iyer SS, Pulskens WP, Sadler JJ, Butter LM, Teske GJ, Ulland TK, Eisenbarth SC, Florquin S, Flavell RA, Leemans JC et al (2009) Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci U S A 106:20388-20393
51. Lauer N, Mihlan M, Hartmann A, Schlötzer-Schrehardt U, Keilhauer C, Scholl HP, Charbel Issa P, Holz F, Weber BH, Skerka C et al (2011) Complement regulation at necrotic cell lesions is impaired by the age-related macular degeneration-associated factor-H His402 risk variant. J Immunol 187:4374-4383
52. Juliana C, Fernandes-Alnemri T, Kang S, Farias A, Qin F, Alnemri ES (2012) Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem 287:36617-36622
53. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J (2010) Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11:136-140
54. Shimada K, Crother TR, Karlin J, Dagvadorj J, Chiba N, Chen S, Ramanujan VK, Wolf AJ, Vergnes L, Ojcius DM et al (2012) Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36:401-414
55. Zhou R, Yazdi AS, Menu P, Tschopp J (2011) A role for mitochondria in NLRP3 inflammasome activation. Nature 469:221-225
56. Lemasters JJ (2005) Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuvenation Res 8:3-5
57. Witte ME, Geurts JJ, de Vries HE, van der Valk P, van Horssen J (2010) Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration? Mitochondrion 10:411-418
58. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9:847-856
59. Bryant C, Fitzgerald KA (2009) Molecular mechanisms involved in inflammasome activation. Trends Cell Biol 19:455-464
60. Schütt F, Bergmann M, Holz FG, Kopitz J (2002) Isolation of intact lysosomes from human RPE cells and effects of A2-E on the integrity of the lysosomal and other cellular membranes. Graefes Arch Clin Exp Ophthalmol 240:983-988
61. Xu H, Chen M, Forrester JV (2009) Para-inflammation in the aging retina. Prog Retin Eye Res 28:348-368
62. Kaneko H, Dridi S, Tarallo V, Gelfand BD, Fowler BJ, Cho WG, Kleinman ME, Ponicsan SL, Hauswirth WW, Chiodo VA et al (2011) DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature 471:325-330
63. Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11:633-652
64. Lavalette S, Raoul W, Houssier M, Camelo S, Levy O, Calippe B, Jonet L, Behar-Cohen F, Chemtob S, Guillonneau X et al (2011) Interleukin-1β inhibition prevents choroidal neovascularization and does not exacerbate photoreceptor degeneration. Am J Pathol 178:2416-2423
65. Arend WP, Palmer G, Gabay C (2008) IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 223:20-38
66. Tak PP, Bacchi M, Bertolino M (2006) Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. Eur J Drug Metab Pharmacokinet 31:109-116
67. von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, Ku CL, Chrabieh M, Mustapha IB, Ghandil P, Camcioglu Y et al (2008) Pyogenic bacterial infections in humans with MyD88 deficiency. Science 321:691-696
68. Gruver AL, Hudson LL, Sempowski GD (2007) Immunosenescence of ageing. J Pathol 211:144-156
69. Dinarello CA (2006) Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr 83:447S-455S
70. Watford WT, Moriguchi M, Morinobu A, O'Shea JJ (2003) The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 14:361-368
71. Seddon JM, George S, Rosner B (2006) Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the US Twin Study of Age-Related Macular Degeneration. Arch Ophthalmol 124:995-1001
72. Zampros I, Praidou A, Brazitikos P, Ekonomidis P, Androudi S (2012) Antivascular endothelial growth factor agents for neovascular age-related macular degeneration. J Ophthalmol 2012:319728
73. Bressler NM (2002) Early detection and treatment of neovascular age-related macular degeneration. J Am Board Fam Pract 15:142-152
74. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D'Amore PA (2008) Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors. PLoS One 3:e3554
75. Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC et al (2013) NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493:674-678